JP2013522311A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522311A5
JP2013522311A5 JP2013500162A JP2013500162A JP2013522311A5 JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5 JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5
Authority
JP
Japan
Prior art keywords
phe
lys
arg
aromatic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013500162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028543 external-priority patent/WO2011116007A1/en
Publication of JP2013522311A publication Critical patent/JP2013522311A/ja
Publication of JP2013522311A5 publication Critical patent/JP2013522311A5/ja
Pending legal-status Critical Current

Links

JP2013500162A 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法 Pending JP2013522311A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31394510P 2010-03-15 2010-03-15
US61/313,945 2010-03-15
US37681310P 2010-08-25 2010-08-25
US61/376,813 2010-08-25
PCT/US2011/028543 WO2011116007A1 (en) 2010-03-15 2011-03-15 Combination therapies using cyclosporine and aromatic cationic peptides

Publications (2)

Publication Number Publication Date
JP2013522311A JP2013522311A (ja) 2013-06-13
JP2013522311A5 true JP2013522311A5 (OSRAM) 2014-05-01

Family

ID=44649559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500162A Pending JP2013522311A (ja) 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法

Country Status (4)

Country Link
US (4) US8697657B2 (OSRAM)
EP (6) EP3375449A1 (OSRAM)
JP (1) JP2013522311A (OSRAM)
WO (1) WO2011116007A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516426A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 冠状動脈バイパス移植術を行うための方法
JP2013516425A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 血管閉塞傷害の予防または治療方法
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN106620645A (zh) * 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
EP3466439A1 (en) 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2013149172A1 (en) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
JP2014196281A (ja) * 2012-08-01 2014-10-16 健輔 江頭 医薬組成物
EP3485897A1 (en) 2012-08-02 2019-05-22 Stealth Peptides International, Inc. D-arg-2'6'-dmt-lys-phe-nh2 for decreasing statin side effects
MX2015005102A (es) * 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
HUE046924T2 (hu) 2013-03-01 2020-03-30 Stealth Biotherapeutics Corp Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
CA2916884C (en) 2013-03-01 2021-02-09 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
EP2996707B1 (en) * 2013-05-14 2019-09-11 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
US20140363391A1 (en) * 2013-06-06 2014-12-11 Demetris Yannopoulos System and method for administering poloxamers and anesthetics while performing cpr and minimizing reperfusion injury
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2916497C (en) 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
WO2015023680A1 (en) * 2013-08-12 2015-02-19 Stealth Peptides International, Inc. Combination therapy for the treatment of ischemia-reperfusion injury
WO2015100376A1 (en) * 2013-12-27 2015-07-02 Stealth Peptides International, Inc. Pharmaceutically relevant aromatic-cationic peptides
JP2017512762A (ja) * 2014-03-03 2017-05-25 ステルス バイオセラピューティックス コープ 薬学的に妥当な芳香族カチオン性ペプチド及びその生成方法
WO2015183988A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including therapeutic small molecules and uses thereof
WO2015183995A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
ES2870481T3 (es) 2014-08-21 2021-10-27 Stealth Biotherapeutics Corp Péptido D-Arg-2’,6’-Dmt-Lys-Phe-NH2 para el tratamiento del síndrome de Alport
US10683534B2 (en) * 2015-01-27 2020-06-16 BioSpyder Technologies, Inc. Ligation assays in liquid phase
US20180042983A1 (en) * 2015-02-13 2018-02-15 Stealth Peptides International, Inc. Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof, and methods of using the same
CA2978905A1 (en) * 2015-03-06 2016-09-15 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3017359A1 (en) * 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
WO2018223032A1 (en) * 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
CN113544138B (zh) * 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2000051625A1 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
JP2003507438A (ja) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
PT1599216E (pt) 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
NZ549393A (en) 2004-01-23 2009-07-31 Cornell Res Foundation Inc Methods for reducing oxidative damage
JP2007532507A (ja) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 脳虚血ならびに脳および脊髄傷害の処置のためのサイクロスポリンの使用
EP2023948A1 (en) * 2006-05-04 2009-02-18 Michel Ovize Use of cyclosporin a or melle4-cyclosporin for the treatment of acute myocardial infarction
WO2008094275A1 (en) * 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
JP5780969B2 (ja) * 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
EP4302829B1 (en) * 2009-08-24 2025-05-21 Stealth BioTherapeutics Inc. Peptide for use in preventing or treating macular degeneration
JP2013516426A (ja) 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 冠状動脈バイパス移植術を行うための方法
JP2013516425A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 血管閉塞傷害の予防または治療方法
EP2528934A4 (en) 2010-01-25 2013-08-21 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
US20130040901A1 (en) * 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Similar Documents

Publication Publication Date Title
JP2013522311A5 (OSRAM)
CA2915005C (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
ES2398012T5 (es) Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
ES2484315T3 (es) Tratamiento de la pérdida del sentido del tacto con derivados de saxitoxina
JP2009102342A5 (OSRAM)
JP2011500851A5 (OSRAM)
JP2011241213A5 (OSRAM)
JP2014515373A5 (OSRAM)
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
JP2013515739A5 (OSRAM)
RU2012131251A (ru) Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
JP2023061943A (ja) ペプチド組成物
JP2013518124A5 (OSRAM)
JP2008517991A5 (OSRAM)
JP2009500045A5 (OSRAM)
JP2016505050A5 (OSRAM)
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
CA2582452A1 (en) Pegylated liposomal doxorubicin in combination with ecteinascidin 743
WO2009151714A3 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
JP2020510043A5 (OSRAM)
TWI496579B (zh) 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途
ES2791301T3 (es) Combinación de canrenoato y exenatida
ES2671024T3 (es) Composición farmacéutica para administración transnasal
BR112019026336A2 (pt) forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico
CN114364691B (zh) 作为纤维化基质积累的抑制剂的肽